Medical Oncology

, Volume 29, Issue 1, pp 324–331 | Cite as

Vasculogenic mimicry–potential target for glioblastoma therapy: an in vitro and in vivo study

  • Yinsheng Chen
  • Zhitao Jing
  • Cheng Luo
  • Minghua Zhuang
  • Junzhe Xia
  • Zhongping Chen
  • Yunjie Wang
Original Paper

Abstract

Glioblastoma is one of the most angiogenic human tumors and characterized by microvascular proliferations. A better understanding of glioblastoma vasculature is needed to optimize anti-angiogenic therapy that has shown a promising but incomplete efficacy. The present study examined 48 glioblastomas by CD34 endothelial marker periodic acid–Schiff (PAS) dual staining and found non-endothelial cell-lined blood vessels that were formed by tumor cells (vasculogenic mimicry, VM) existing in a fraction of these tumors. We hypothesized that CD133-positive glioblastoma stem-like cells (GSCs) may play a pivotal role in glioblastoma VM formation and then demonstrated in vitro and in vivo that a subset of GSCs were capable of vasculogenesis. Moreover, we found that several growth factors involved in normal angiogenesis were expressed in GSCs. We describe here a new mechanism of alternative glioblastoma vascularization and open a new perspective for the anti-vascular treatment strategy.

Keywords

Glioblastoma Angiogenesis Vasculogenic mimicry Stem cell 

References

  1. 1.
    Shrieve DC, Alexander E 3rd, Black PM, Wen PY, Fine HA, et al. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg. 1999;90(1):72–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(5):97–109.PubMedCrossRefGoogle Scholar
  3. 3.
    Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(4):1253–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Kreisl TN, Kim L, Moore K, Duic P, Royce C, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999;155(3):739–52.PubMedCrossRefGoogle Scholar
  6. 6.
    Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res. 2001;61(2):445–51.PubMedGoogle Scholar
  7. 7.
    Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW, et al. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology. 2010;51(2):545–56.PubMedCrossRefGoogle Scholar
  8. 8.
    Passalidou E, Trivella M, Singh N, Ferguson M, Hu J, et al. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer. 2002;86(2):244–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Sood AK, Seftor EA, Fletcher MS, Gardner LM, Heidger PM, et al. Molecular determinants of ovarian cancer plasticity. Am J Pathol. 2001;158(4):1279–88.PubMedCrossRefGoogle Scholar
  10. 10.
    Sharma N, Seftor RE, Seftor EA, Gruman LM, Heidger PM Jr, et al. Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate. 2002;50(3):189–201.PubMedCrossRefGoogle Scholar
  11. 11.
    Favier J, Plouin PF, Corvol P, Gasc JM. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol. 2002;161(4):1235–46.PubMedCrossRefGoogle Scholar
  12. 12.
    Hao X, Sun B, Zhang S, Zhao X. Microarray study of vasculogenic mimicry in bi-directional differentiation malignant tumor. Zhonghua Yi Xue Za Zhi. 2002;82(19):1298–302. (in Chinese).PubMedGoogle Scholar
  13. 13.
    Yue WY, Chen ZP. Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem. 2005;53(8):997–1002.PubMedCrossRefGoogle Scholar
  14. 14.
    Hallani SEI, Boisselier B, Peglion F, Rousseau A, Colin C, et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain. 2010;133(Pt4):973–82.PubMedCrossRefGoogle Scholar
  15. 15.
    Guzman G, Cotler SJ, Lin AY, Maniotis AJ, Folberg R. A pilot study of vasculogenic mimicry immunohistochemical expression in hepatocellular carcinoma. Arch Pathol Lab Med. 2007;131(12):1776–81.PubMedGoogle Scholar
  16. 16.
    Sun B, Qie S, Zhang S, Sun T, Zhao X, et al. Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors. Hum Pathol. 2008;39(3):444–51.PubMedCrossRefGoogle Scholar
  17. 17.
    Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol. 2000;156(2):361–81.PubMedCrossRefGoogle Scholar
  18. 18.
    Huang Q, Zhang QB, Dong J, Wu YY, Shen YT, et al. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro. BMC Cancer. 2008;8:304.PubMedCrossRefGoogle Scholar
  19. 19.
    Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284(5422):1994–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Santarelli JG, Udani V, Yung YC, Cheshier S, Wagers A, et al. Incorporation of bone marrow-derived Flk-1-expressing CD34 + cells in the endothelium of tumor vessels in the mouse brain. Neurosurgery. 2006;59(2):374–82.PubMedCrossRefGoogle Scholar
  21. 21.
    Kurz H, Burri PH, Djonov VG. Angiogenesis and vascular remodeling by intussusception: from form to function. News Physiol Sci. 2003;18:65–70.PubMedGoogle Scholar
  22. 22.
    Dong J, Zhang QB, Huang Q, Chen H, Shen YT, et al. Glioma stem cells involved in tumor tissue remodeling in a xenograft model. J Neurosurg. 2010;113:249–60.PubMedCrossRefGoogle Scholar
  23. 23.
    Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. Identification of human brain tumor initiating cells. Nature. 2004;432(7015):396–401.PubMedCrossRefGoogle Scholar
  24. 24.
    Tso CL, Shintaku P, Chen J, Liu Q, Liu J, et al. Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res. 2006;4(3):607–19.PubMedCrossRefGoogle Scholar
  25. 25.
    Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006;66(16):7843–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Ezhilarasan R, Mohanam I, Govindarajan K, Mohanam S. Glioma cells suppress hypoxia-induced endothelial cell apoptosis and promote the angiogenic process. Int J Oncol. 2007;30(3):701–7.PubMedGoogle Scholar
  27. 27.
    Udani V, Santarelli J, Yung Y, Cheshier S, Andrews A, et al. Differential expression of angiopoietin-1 and angiopoietin-2 may enhance recruitment of bone-marrow-derived endothelial precursor cells into brain tumors. Neurol Res. 2005;27(8):801–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18):5821–8.PubMedGoogle Scholar
  29. 29.
    Oka N, Soeda A, Inagaki A, Onodera M, Maruyama H, et al. VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem Biophys Res Commun. 2007;360(3):553–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359(6398):845–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235:442–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Thomas KA, Gimenez-Gallego G. Fibroblast growth factors: broad spectrum mitogens with potent angiogenic activity. Trends Biochem Sci. 1986;11:81–4.CrossRefGoogle Scholar
  33. 33.
    Thomas KA. Fibroblast growth factors. FASEB J. 1987;1(6):434–40.PubMedGoogle Scholar
  34. 34.
    Wang D, Huang HJ, Kazlauskas A, Cavanee WK. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res. 1999;59(7):1464–72.PubMedGoogle Scholar
  35. 35.
    Goldman CK, Kim J, Wong WL, King V, Brock T, et al. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell. 1993;4(1):121–33.PubMedGoogle Scholar
  36. 36.
    Valter MM, Wiestler OD, Pietsche T. Differential control of VEGF synthesis and secretion in human glioma cells by IL-1 and EGF. Int J Dev Neurosci. 1999;17(5–6):565–77.PubMedCrossRefGoogle Scholar
  37. 37.
    Van der Schaft DW, Seftor RE, Seftor EA, Hess AR, Gruman LM, et al. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst. 2004;96(19):1473–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Mei J, Gao Y, Zhang L, Cai X, Qian Z, et al. VEGF-siRNA silencing induces apoptosis, inhibits proliferation and suppresses vasculogenic mimicry in osteosarcoma in vitro. Exp Oncol. 2008;30(1):29–34.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Yinsheng Chen
    • 1
  • Zhitao Jing
    • 1
  • Cheng Luo
    • 2
  • Minghua Zhuang
    • 2
  • Junzhe Xia
    • 1
  • Zhongping Chen
    • 3
    • 4
  • Yunjie Wang
    • 1
  1. 1.Department of Neurosurgery, The First Affiliated HospitalChina Medical UniversityShenyangPeople’s Republic of China
  2. 2.Department of Neurosurgery, The First Affiliated HospitalShantou University Medical CollegeShantouPeople’s Republic of China
  3. 3.State Key Laboratory for Cancer Research in Southern ChinaSun Yat-sen UniversityGuangzhouPeople’s Republic of China
  4. 4.Department of Neurosurgery/Neuro-oncology, Cancer CenterSun Yat-sen UniversityGuangzhouPeople’s Republic of China

Personalised recommendations